227 related articles for article (PubMed ID: 33782497)
1. Sensitivity of cells to ATR and CHK1 inhibitors requires hyperactivation of CDK2 rather than endogenous replication stress or ATM dysfunction.
Ditano JP; Donahue KL; Tafe LJ; McCleery CF; Eastman A
Sci Rep; 2021 Mar; 11(1):7077. PubMed ID: 33782497
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of checkpoint kinase 1 following gemcitabine-mediated S phase arrest results in CDC7- and CDK2-dependent replication catastrophe.
Warren NJH; Eastman A
J Biol Chem; 2019 Feb; 294(6):1763-1778. PubMed ID: 30573684
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the different mechanisms of cytotoxicity induced by checkpoint kinase I inhibitors when used as single agents or in combination with DNA damage.
Warren NJH; Eastman A
Oncogene; 2020 Feb; 39(7):1389-1401. PubMed ID: 31659257
[TBL] [Abstract][Full Text] [Related]
4. Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in
Kim H; George E; Ragland R; Rafail S; Zhang R; Krepler C; Morgan M; Herlyn M; Brown E; Simpkins F
Clin Cancer Res; 2017 Jun; 23(12):3097-3108. PubMed ID: 27993965
[No Abstract] [Full Text] [Related]
5. Inhibition of the ATR-CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2.
Koppenhafer SL; Goss KL; Terry WW; Gordon DJ
Mol Cancer Res; 2020 Jan; 18(1):91-104. PubMed ID: 31649026
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
Massey AJ
Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461
[TBL] [Abstract][Full Text] [Related]
7. Differential Sensitivity to CDK2 Inhibition Discriminates the Molecular Mechanisms of CHK1 Inhibitors as Monotherapy or in Combination with the Topoisomerase I Inhibitor SN38.
Warren NJH; Donahue KL; Eastman A
ACS Pharmacol Transl Sci; 2019 Jun; 2(3):168-182. PubMed ID: 32259055
[TBL] [Abstract][Full Text] [Related]
8. Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S Phase.
Buisson R; Boisvert JL; Benes CH; Zou L
Mol Cell; 2015 Sep; 59(6):1011-24. PubMed ID: 26365377
[TBL] [Abstract][Full Text] [Related]
9. Loss of Cyclin C or CDK8 provides ATR inhibitor resistance by suppressing transcription-associated replication stress.
Lloyd RL; Urban V; Muñoz-Martínez F; Ayestaran I; Thomas JC; de Renty C; O'Connor MJ; Forment JV; Galanty Y; Jackson SP
Nucleic Acids Res; 2021 Sep; 49(15):8665-8683. PubMed ID: 34329458
[TBL] [Abstract][Full Text] [Related]
10. Chronic treatment with ATR and CHK1 inhibitors does not substantially increase the mutational burden of human cells.
Casimir L; Zimmer S; Racine-Brassard F; Goudreau F; Jacques PÉ; Maréchal A
Mutat Res; 2023; 827():111834. PubMed ID: 37531716
[TBL] [Abstract][Full Text] [Related]
11. The Influence of PARP, ATR, CHK1 Inhibitors on Premature Mitotic Entry and Genomic Instability in High-Grade Serous
Gralewska P; Gajek A; Rybaczek D; Marczak A; Rogalska A
Cells; 2022 Jun; 11(12):. PubMed ID: 35741017
[TBL] [Abstract][Full Text] [Related]
12. Comparative Activity and Off-Target Effects in Cells of the CHK1 Inhibitors MK-8776, SRA737, and LY2606368.
Ditano JP; Eastman A
ACS Pharmacol Transl Sci; 2021 Apr; 4(2):730-743. PubMed ID: 33860197
[TBL] [Abstract][Full Text] [Related]
13. Chk1 inhibition induces a DNA damage bystander effect in cocultured tumour cells.
Brooks T; Wayne J; Massey AJ
DNA Repair (Amst); 2021 May; 101():103099. PubMed ID: 33740539
[TBL] [Abstract][Full Text] [Related]
14. A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase.
Sakurikar N; Thompson R; Montano R; Eastman A
Oncotarget; 2016 Jan; 7(2):1380-94. PubMed ID: 26595527
[TBL] [Abstract][Full Text] [Related]
15. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
[TBL] [Abstract][Full Text] [Related]
16. Cdk inhibition in human cells compromises chk1 function and activates a DNA damage response.
Maude SL; Enders GH
Cancer Res; 2005 Feb; 65(3):780-6. PubMed ID: 15705874
[TBL] [Abstract][Full Text] [Related]
17. Distinct roles for DNA-PK, ATM and ATR in RPA phosphorylation and checkpoint activation in response to replication stress.
Liu S; Opiyo SO; Manthey K; Glanzer JG; Ashley AK; Amerin C; Troksa K; Shrivastav M; Nickoloff JA; Oakley GG
Nucleic Acids Res; 2012 Nov; 40(21):10780-94. PubMed ID: 22977173
[TBL] [Abstract][Full Text] [Related]
18. Chk1- and claspin-dependent but ATR/ATM- and Rad17-independent DNA replication checkpoint response in HeLa cells.
Rodríguez-Bravo V; Guaita-Esteruelas S; Florensa R; Bachs O; Agell N
Cancer Res; 2006 Sep; 66(17):8672-9. PubMed ID: 16951182
[TBL] [Abstract][Full Text] [Related]
19. SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance.
Llorca-Cardenosa MJ; Aronson LI; Krastev DB; Nieminuszczy J; Alexander J; Song F; Dylewska M; Broderick R; Brough R; Zimmermann A; Zenke FT; Gurel B; Riisnaes R; Ferreira A; Roumeliotis T; Choudhary J; Pettitt SJ; de Bono J; Cervantes A; Haider S; Niedzwiedz W; Lord CJ; Chong IY
Cancer Res; 2022 Nov; 82(21):3962-3973. PubMed ID: 36273494
[TBL] [Abstract][Full Text] [Related]
20. ATR and Chk1 suppress a caspase-3-dependent apoptotic response following DNA replication stress.
Myers K; Gagou ME; Zuazua-Villar P; Rodriguez R; Meuth M
PLoS Genet; 2009 Jan; 5(1):e1000324. PubMed ID: 19119425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
